

NIH Common Fund HuBMAP / SCAP Mini Workshop Neuroscience Center, Bethesda, MD

WEDNESDAY, JUNE 28, 2017

12:20 pm **Introductory Remarks - Robert Star (Director Division of Kidney, Urologic, and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases, HuBMAP Co-Chair)**

12:30 – 2:30pm Challenges in collecting and pre-analytical processing of tissue

Moderator: Robert Star (NIDDK)

There are many tissue collection and processing factors that influence data quality, from length of ischemia time to storage conditions and collection method. These factors influence the distribution and degradation of biomolecules at different rates. Therefore, it is critical to match the choice of tissue source, collection method and preservation technique with the types of biomolecules being studied by different downstream assays.

The purpose of this session is to identify some of the challenges in collecting, preserving, and annotating high quality human tissue that will be used for downstream analytical techniques in the HuBMAP program. These techniques include single cell RNAseq, FISH, immuno-fluorescence as well as emerging techniques such as MERFISH, FISSEQ, seqFISH, MIBI-TOF, and 3-dimensional high-end imaging. Through the discussion, we hope to have a better understanding of the challenges HuBMAP might face in collecting and pre-analytical processing of tissue specimens and how this processing will impact the quality of data collected by different single cell, tissue, and imaging assays.

A number of components add to these challenges. One component is to record the spatial orientation of samples relative to anatomical landmarks (and build this into the sample management pipeline). A second component is the analysis, then integration and iteration of data from multiple imaging and omics assays to develop comprehensive molecular (and omic) profiles of the cells within the tissue, including location information. A third key component is to understand when sources of variability are biologically relevant (within tissue samples from same patient, across multiple tissues, and across multiple donors) or artifacts of the collection and processing of the samples.

Questions for the breakout session to consider include:

- **Quality:** What are practical quality measures for assessing the impact of tissue collection methods and the degree of degradation? How does the magnitude of ischemia signatures compare with collection, dissociation or storage signatures? Is there a common set of quality biomarkers that can be used across all tissues and that are compatible with downstream assays?
- **Metadata:** Beyond SPREC 2.0, are there common data elements describing collection and processing that are relevant to mapping DNA, RNA and proteins biomolecular distributions in tissues?
- **Assay Workflow:** What are best practices for assessing the impact of single cell (liberase) and tissue (LCM, super-resolution, imaging MS/MS) based tissue “dissociation” methods on assay measurements? Can tissue sections be used for multiple assays (RNA in situ, then protein, then routine stains)?
- **Collection:** For what assays and tissue types do tissues need to be collected from live donors? Rapid autopsy protocols?
- **Staining:** Do common stains (e.g. H&E, trichrome, toluidine) influence the sensitivity and specificity of downstream assays?
- **Orientation:** How do we preserve orientation of a tissue specimen through the processing chain?

- Fixing, clearing and embedding: Are there tissue stabilization techniques that can be used before or during collection? For current and emerging fixatives/preservatives of excised tissue, which biomolecular species do they preserve with good fidelity (not only nucleic acids and proteins, but how effective are these techniques at preserving metabolites or carbohydrates), what compatibility issues are there with different tissue types, cell types, dissociation techniques and assays? What are some of the challenges associated with clearing techniques?
- Sectioning: What are tissue-specific considerations in preparing tissue sections? How does the choice of tissue size and format influence ischemia and preservation timing and in term the quality of the tissue for different downstream assays?
- End-users: What format, quantity, and quality level is needed for: RNAseq, DropSeq, MERFISH / FISSEQ / seqFISH, immuno-florescence, MIBI-TOF and CyTOF approaches?

2:30 – 3:00pm Break

3:00 – 5:00 pm Data Analysis, Standards, and Benchmarks for Single Cell Analysis

Moderator: Junhyong Kim (University of Pennsylvania)

Because of the difficulty of obtaining measurements at the single cell scale, the field has been driven by technological advances, including various RNA/DNA sequencing technologies, high-resolution proteomics and metabolomics, multiplexing strategies, cell handling technologies, etc. Despite these technological advances, single cell measurements remain difficult and is fundamentally challenged by the fact that the units of measurement, each cell, has no replication. It has been extremely difficult to assess the efficiency of measurements, establish benchmarks or controls, agree on protocols for data analysis, and coherently define standards for reporting experiments and data analysis. An especially important challenge is placing single cell data in their organismal context, including spatial coordinates.

Questions for this breakout session to consider include:

- Is there benchmark data to compare new experimental or computational methods?
- How do we establish material standards such as specific cells or spike-in RNA?
- What metadata about calibration is important to know?
- What information is important to collect about the sample and its preparation?
- How can we work together with manufacturers to build standards into their methods?
- Does an ontology need to be established for single cell analysis?
- How can we associate single cells to tissue orientation information? More generally, how can data be organized from the single cell scale to whole organism scale?
- What are the common data elements between imaging and sequencing assays? Is there a common header we can use for all data, similar to FITS or DICOM?

5:00 pm Closing Remarks

Suggested background reading for these breakouts:

- Unhale, S. A., Skubitz, A. P., Solomon, R., & Hubel, A. (2012). Stabilization of tissue specimens for pathological examination and biomedical research. *Biopreservation and biobanking*, 10(6), 493-500. [<http://online.liebertpub.com/doi/abs/10.1089/bio.2012.0031>]
- Hubel, A., Spindler, R., & Skubitz, A. P. (2014). Storage of human biospecimens: selection of the optimal storage temperature. *Biopreservation and biobanking*, 12(3), 165-175. [<http://online.liebertpub.com/doi/abs/10.1089/bio.2013.0084>]
- Hubel, A., Aksan, A., Skubitz, A. P., Wendt, C., & Zhong, X. (2011). State of the art in preservation of fluid biospecimens. *Biopreservation and biobanking*, 9(3), 237-244. [<http://online.liebertpub.com/doi/abs/10.1089/bio.2010.0034>]
- Chung, Cho H, Hewitt SM (2016). The paraffin-embedded RNA metric (PERM) for RNA isolated from formalin-fixed, paraffin-embedded tissue. *Biotechniques*. May 1;60(5):239-44 [<http://www.biotechniques.com/BiotechniquesJournal/2016/May/The-paraffin-embedded-RNA-metric-PERM-for-RNA-isolated-from-formalin-fixed-paraffin-embedded-tissue/biotechniques-364401.html>]
- Carithers, L. J., Ardlie, K., Barcus, M., Branton, P. A., Britton, A., Buia, S. A., ... & Guan, P. (2015). A novel approach to high-quality postmortem tissue procurement: the GTEx project. *Biopreservation and biobanking*, 13(5), 311-319. [<http://online.liebertpub.com/doi/full/10.1089/bio.2015.0032>]



**NIH Common Fund
Single Cell Analysis Program
(SCAP)**

**Human BioMolecular Atlas
Program (HuBMAP)**

**Tissue Acquisition and
Metadata Standards Workshop**

**Robert A. Star, MD
NIDDK**

Disclosure

My laboratory is involved in research to improve pre-analytic processing steps after tissue biopsy.

I am an inventor on a provisional patent application for a **tissue transfer device** that reduces tissue damage after biopsy.

I am an inventor on a provisional patent application for a **chemically engineered fixative** (BE70G) that does not contain formaldehyde, and improves molecular analyses.

If NIH successfully commercializes the inventions, I **may receive royalty payments** using standard NIH formulas.



NIH HuBMAP Working Group

Co-Chairs:

Gary Gibbons, M.D. (NHLBI)
Roderic Pettigrew, Ph.D., M.D. (NIBIB)
Robert Star, M.D. (NIDDK)

Working Group Coordinators:

Zorina Galis, Ph.D. (NHLBI)
Deborah K. Hoshizaki, Ph.D. (NIDDK)

Common Fund Program Leader:

Richard Conroy, Ph.D., M.B.A. (OD)

Members:

David Balasundaram, Ph.D.(CSR)
Jenna Baker, Ph.D.(NIDDK)
Andrea Beckel-Mitchener, Ph.D. (NIMH)
Francesca Bosetti, Pharm. D., Ph.D. (NINDS)
Katarzyna Bourcier, Ph.D. (NIAID)
Robert Carter, M.D. (NIAMS)
Tony Casco (OD)
Elizabeth Church, Ph.D. (NIAID)
Jennifer Couch, Ph.D. (NCI)
Sarah Dunsmore, Ph.D. (NIGMS)

Joseph G. Gindhart, Ph.D. (NIGMS)
Patricia Greenwel, Ph.D. (NIDDK)
Jill Heemskerk, Ph.D. (NIBIB)
Shannon Hughes, Ph.D. (NCI)
Halonna Kelly, Ph.D. (NIAID)
J. Randy Knowlton, Ph.D. (NCI)
Lillian S. Kuo, Ph.D. (NIAID)
Jerry Li, Ph.D. (NCI)
Sara Lin, Ph.D. (NHLBI)
Margaret Ochocinska, Ph.D. (NHLBI)
Aaron Pawlyk, Ph.D. (NIDDK)
Ajay Pillai, Ph.D. (NHGRI)
Ipolia Ramadan, Ph.D. (NINDS)
Krystyna Rys-Sikora, Ph.D. (NIDDK)
John Satterlee, Ph.D. (NIDA)
Tonya Scott (OD)
Salvatore Sechi, Ph.D. (NIDDK)
Kentner Singleton, Ph.D. (NIAID)
Jessica Smith, Ph.D.(OD)
Pothur Srinivas, Ph.D. (NHLBI)
Reiko Toyama, Ph.D. (NICHD)
José M. Velázquez, Ph.D. (NIA)
Yong Yao, Ph.D. (NIMH)

HuBMAP: Background

- In past, cells classified by structure, function, location in tissue, histologic staining
- Opportunity:
 - Massively parallel single cell analysis (genomics) **assays**
 - Computational **algorithms** to find types, sub-types, states, transitions;
 - **Imaging** at growing scale and resolution
- New paradigm: Classify cells and tissue components based on molecular omic profile
- Critical questions (for example)
 - How do cells vary within structure; within tissue; across tissues, systems, and organs (vasculature, supportive cells).
 - Are there undiscovered sub-compartments, rare cells
 - How do cells interact (ligands, receptors)
 - How do cells influence health and disease



HuBMAP Goals

The overall goal of HuBMAP is to catalyze the development of **a comprehensive atlas of cellular/tissue organization** in human tissues that will elucidate the principles of organization-function by:

- accelerating **development of tools** for constructing comprehensive spatial tissue maps and integrating data types,
- building and **generating tissue maps** from validated high-content, high-throughput imaging and omics assays,
- **coordinating and collaborating** with other funding agencies, programs and the biomedical research community,
- rapidly making **data findable, accessible, interoperable, and reusable** in standardized formats.



HuBMAP Vision

If successful, this program will lead to a data resource like **“Google Maps” for tissues** in the human body

that will *give rise to* new insights **into inter-individual variation and tissue changes across the lifespan**, and serve as baseline for **understanding disease**.


What is a tissue atlas?

Kidney pathology of the future




Analyze single cells/tissue to find **tissue markers** (cells, and interstitial areas between cells)
then **paint** cells, structures, cell trajectory (healthy, injured, repair, regen), activated pathways
Understand heterogeneity between regions, neighboring cells
Even better, use 3D imaging to better see interstitium, glomerulus


Generating Tissue Maps



In vivo Imaging
(if possible)



Tissue
Collection



Reference
Atlas



Histology,
Fiducials &
Annotation



Preservation
and QC

Key Elements

- **Comprehensive profiling**
- **3D Spatial coordinate system**
- **Iterative imaging and omics**

Species: DNA, RNA,
Protein, Metabolites ...

Methods: WGA, LIANTI,
RNAseq, ChIPseq, MALDI,
ATACseq, CyTOF...

Dissociative






Laser
capture,
Spatial
encoding,
On tissue
processing ...

Species: DNA, RNA,
Protein, Metabolites ...

Methods: IHC, FISH,
seqFISH, MERFISH,
FISSEQ, MIBI-TOF...

In Situ

Kidney Precision Medicine Project workflow (modified for HuBMAP)




Obtain tissue

Learn from tissue
Find components
Find markers

Evaluate markers on tissue

Find cell pathway markers; tie to Patient outcomes

Create Kidney Tissue Atlas



Identifying Key Areas in a Human BioMolecular Atlas

Planning Workshop
June 15, 2016

Areas with challenges and opportunities for investment by the NIH:

1. Sourcing high quality tissue from multiple organ sites
2. Processing and preserving tissue for multiple imaging and omics assays
3. Quality control, validation and variation in data generation
4. Data coordination across multiple acquisition techniques
5. Annotation, curation and archiving of the data
6. Browsing, visualizing and searching the data
7. Building statistical and analytic techniques and models for nonlinear analysis of highly multidimensional data
8. Community engagement



Challenges in collecting and pre-analytical processing of tissue

Data analysis, standards, and benchmarks for single cell analysis

Questions?



What's next?

- FOAs this Fall
- Program rolled out in phases
- Mini workshop June 28, 2017
 - Pre-analytic processing
 - Metadata
- Single Cell Analysis
Investigators Meeting, June 29-30, 2017



Challenges in collecting and pre-analytical processing of tissue


Robert A. Star, MD
NIDDK

Pre-analytic processing of tissue samples


- Tissue collection and processing influences sample quality and composition. Distribution and degradation of biomolecules occur at different rates. Critical to match initial steps to downstream uses
- Optimize
 - Tissue source, collection method: Live donor vs warm autopsy vs ??
 - Initial preservation and storage
 - Initial processing: clearing, embedding, sectioning
 - Sample/assay workflow
 - Quality control for each step
- Are there overarching considerations to maximize quality, minimize artifact?
- Dark matter



Simplified HuBMAP Workflow



Many areas for Improvement



Examples of dark matter

Tissue preservation / fixation step

- Formalin bad for RNA, some proteins ('antigen retrieval')
- Frozen bad for histology
- Fresh tissue is fragile
- Need better preservation steps that match preservation to intended downstream uses (fit for context)

Single cell dissociation step



- Digestion (37°C) leaves mRNA signature
- Selective for mobile inflammatory cells
- Not many cells analyzed
- Very few structural (organ) cells analyzed
- Need less destructive dissociation technologies

How to make espresso



How avoid sour or bitter espresso?

Grid, volume, temperature influence extraction, and taste. Need optimization process



Bottom line: difficult, need balance multiple factors

Innovation: Look for alternative



- **Orientation:** How do we preserve orientation of a tissue specimen through the processing chain?
- **Fixing, clearing and embedding:** Are there tissue stabilization techniques that can be used before or during collection? For current and emerging fixatives/preservatives of excised tissue, which biomolecular species do they preserve with good fidelity (not only nucleic acids and proteins, but how effective are these techniques at preserving metabolites or carbohydrates), what compatibility issues are there with different tissue types, cell types, dissociation techniques and assays? What are some of the challenges associated with clearing techniques?
- **Sectioning:** What are tissue-specific considerations in preparing tissue sections? How does the choice of tissue size and format influence ischemia and preservation timing and in term the quality of the tissue for different downstream assays?
- **End-users:** What format, quantity, and quality level is needed for: RNAseq, DropSeq, MERFISH / FISSEQ / seqFISH, immunofluorescence, MIBI-TOF and CyTOF approaches?

- **Quality:** What are practical quality measures for assessing the impact of tissue collection methods and the degree of degradation? How does the magnitude of ischemia signatures compare with collection, dissociation or storage signatures? Is there a common set of quality biomarkers that can be used across all tissues and that are compatible with downstream assays?
- **Metadata:** Beyond SPREC 2.0, are there common data elements describing collection and processing that are relevant to mapping DNA, RNA and proteins biomolecular distributions in tissues?
- **Assay Workflow:** What are best practices for assessing the impact of single cell (liberase) and tissue (LCM, super-resolution, imaging MS/MS) based tissue “dissociation” methods on assay measurements? Can tissue sections be used for multiple assays (RNA in situ, then protein, then routine stains)?
- **Collection:** For what assays and tissue types do tissues need to be collected from live donors? Rapid autopsy protocols?
- **Staining:** Do common stains (e.g. H&E, trichrome, toluidine) influence the sensitivity and specificity of downstream assays?

Why are we here?

- What is working, working well?
- What are the weak links in chain?
- What tools, techniques are needed before going into production phase?





National Institute of Diabetes and Digestive and Kidney Diseases

*and Kidney Diseases
Diabetes and Digestive
National Institute of*



The image features a background of water splashing, with bubbles and droplets visible. The BioCoR logo is positioned in the upper left corner, with the text "BioCoR" in a large, blue, sans-serif font. Below the logo, the tagline "Advancing the science, technology and practice of bio-preservation" is written in a smaller, blue, sans-serif font.


BioCoR

Advancing the science, technology
and practice of bio-preservation

Advancing the preservation of tissue biospecimens

Allison Hubel, PhD

Biopreservation Core Resource (BioCoR) Univer
sity of Minnesota



Processing


**Time
Distance**

Collection

**Time
Distance**

Use

BioCoR Resources




BioCoR Service

- PDX models have complex work flow
- Viability must be maintained along this workflow

BioCoR tasks:

- Develop short term storage solution suitable for resected tumors
- Develop effective cryopreservation protocols for xenografts




InTechOpen.com

Education Resource

BioCoR library



The screenshot shows the BioCoR library website. At the top, there is a navigation bar with links for Home, BioCoR Resources, Library, About, Contact, and Login. A 'Sign Up For Education' button is also visible. Below the navigation bar, the 'Library' section is highlighted, with a description: 'Find a wide range of resources related to biopreservation here: (1) research and news articles on preservation, (2) answers to FAQs on biopreservation, (3) published preservation protocols and much more.' To the right of this text are buttons for 'Submit A Service Request' and 'Subscribe to our Newsletter'. Below the navigation bar, there is a search bar with the text 'Search here...' and a 'Go!' button. The main content area is titled 'BioCoR Library' and contains a list of resources with titles such as 'What is the 'shelf life' of hematopoietic stem cells stored on liquid nitrogen?', 'Do you know of any article showing analyte degradation in plasma or serum when being stored in -80?', 'New technique to preserve blood', 'Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions', 'Post Thaw Recovery of CD34+ Cells > 100%', 'Alternatives to DMSO', 'One common error with post thaw assesment', 'Pooling and re-freezing cells', 'What to freeze in bags, vials, straws?', and 'Storage conditions influence post thaw recovery'. To the right of the main content area, there is a 'BioCoR Resources' section with links for 'Service Request Form', 'Services Resource', 'BioCoR Research Resources', 'Education Resources', 'News & Other Industry Research', 'BioCoR in the News', 'Archived Newsletters', 'Articles of Interest', and 'FAQ - Your questions'. At the bottom of the page, there are page numbers '1 2 3 4 Next >'.



Online short courses in preservation

NHLBI training grant



Monthly newsletter

www.biocor.umn.edu



UNIVERSITY OF MINNESOTA
Driven to Discover™

BioCoR Research

Why do tissues respond poorly (compared to cells isolated from the same tissue)?


Freezing response of isolated iPS cells (Imaged at -50°C)

| | | | | | | | | | |
|----------------------------------|-----------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1 $^{\circ}\text{C}/\text{min}$ | Ice | | | | | | | | |
| | Area/ μm^2 | 104.8 | 105.8 | 71.6 | 94.5 | 114.7 | 81.5 | 111.8 | 138.5 |
| | Aic-s | 0.15 | 0.07 | 0 | 0 | 0 | 0 | 0.12 | 0.16 |
| 3 $^{\circ}\text{C}/\text{min}$ | Ice | | | | | | | | |
| | Area/ μm^2 | 113.2 | 74.6 | 160.2 | 129.0 | 117.8 | 118.2 | 132.1 | 119.8 |
| | Aic-s | 0.08 | 0.26 | 0.37 | 0.42 | 0.15 | 0.24 | 0.33 | 0 |
| 10 $^{\circ}\text{C}/\text{min}$ | Ice | | | | | | | | |
| | Area/ μm^2 | 148.3 | 159.1 | 223.6 | 128.6 | 252.6 | 189.1 | 157.7 | 132.3 |
| | Aic-s | 0.11 | 0.49 | 0.67 | 0.43 | 0.65 | 0.46 | 0.20 | 0.29 |

Scale bar: 3 μm



BioCoR Research



- We can interrogate
 - small aggregates (3-5 cells)
 - Full sized colonies
- A wide range of signals can be detected
 - Water (liquid or ice)
 - DMSO
 - Cryoprotective agents
 - Proteins
 - DNA
- These signals can help answer the central questions



Five to ten years from now...

- Dispel the myth of the 'cold black box'
- Improve and disseminate preservation protocols
- Improve preservation of tissue



Acknowledgements

Collaborators:

Peter Dosa

Dave McKenna

Jane Vanderkooi

Students:

Katie Pollock

Guanglin Yu

Rui Li

Yan Rou Yap

Elizabeth Moy

Chia Hsing Pi

Marissa Koran

Funding:

R21EB016247

R25HL128372





Disclosures

- “Employee” Of The US Federal Government
 - Inventor On Multiple Technologies For Which The Intellectual Property Is Assigned To The Federal Government
 - For Those Inventions That Are Licensed, I Am Eligible To Receive Royalties, As Stipulated In US Code, Title 15, Chapter 63.
- Editor-in-Chief, *Journal of Histochemistry & Cytochemistry*
- Chair-holder, Subcommittee on Immunohistochemical Assays, Clinical & Laboratory Standards Institute
- Food & Drug Administration, Center For Devices & Radiological Health
 - Consultant, Hematology & Pathology Devices Panel

Quality Is Everything

Quality Remains Subjective

- Tissue Quality
 - Histology
 - Proteins
 - Nucleic Acids
- Clinical Data
 - Complete
 - Detailed
 - Defined



Development of A Tissue Handling Protocol

- Historic Perspective

- Histology & Protein – FFPE

Small Study- Frozen

- Nucleic Acids – Frozen

Large Study – FFPE

- Recommended Strategy

- Fit-For-Purpose

Define Goals

- Physiology Is Biology


- Specimen Preservation Is Chemistry

Chemical Preservation

- Formalin
- PaxGene
- Ethanol
-
- Lack Of Scientific Underpinning
- Two Broad Classes
 - Acid/Aldehyde Fixatives
 - Coagulative Fixatives
- Underlying Critical Factors
 - Ischemia
 - Size
 - Time Temp?
 - Impregnation
 - Storage


RNA Recovery - Quantity

- First Study To Address RNA Recovery Based On Equal Volumes Of Starting Material
- FFPE Demonstrates A 30% Recovery
- Ethanol-fixed, PE Has A Recovery Of 80%
 - Formalin Contributes To the Majority Of The Damage




RNA Recovery From Tissue


RNA In Frozen Tissue




RNA In FFPE -Anticipated




RNA In FFPE -Revised



Results Of RT-PCR




Quantitative Amplification Based On RNA Source & Primer Location




Tissue Collection, Handling & Processing

- No Such Thing As "*Standard Protocol*"
- Multiple Steps, Multiple Parameters





Effect Of Fixation Time On RNA Quality


B



Measuring The Effects Quantitatively




- Branch DNA Based Assays
 - Nucleic Acid ELISA
 - No Enzymatic Steps








Schematic Of Process

Formalin Fixed Paraffin Embedded Tissue



Revised Model Of Chemical Fixation

- Tissue Hypoxia & Switching To Glycolysis - *"Drowning"*
 - RNA stores consumed, Alterations in Phospho-Proteome
- Infiltration & Inhibition Of Glycolysis & Oxidative Phosphorylation
 - Halting Of Most Biologic Process
- Chemical Reactions Crosslinking Proteins and Nucleic Acids
 - Halting Of Remaining Enzymatic Activity



Chemical Fixation

- Aldehyde Fixatives Are Two-Step Fixatives
 - Coagulative
 - Acid/Aldehyde Crosslinking - Degradation
- Alcohol Fixatives Are Single-Step Fixatives
 - Coagulative
 - No Acid-Base Degradative Chemistry
- Coagulative Fixatives Are More Stable & Result In Improved Biomolecular Analytes

Experimental Pathology Laboratory

Laboratory of Pathology, Center for Cancer Research,
National Cancer Institute, National Institutes of Health

Joon-Yong Chung

Hanbyoul Cho

Gandice Perry

Jeffrey Hansen

Food & Drug Administration

Center For Device & Radiologic Health

NEPTUNE / CureGN

Kris Ylaya

Russell Bandle

Philip Song

Former Laboratory Members

Till Braunschweig

Mikiko Takikita

Ran Xie

Haru Kitano

Victoria Burton

Kimberly Tuttle

Langston Lim

Petra Lenz

Kant Matsuda

Catherine Conway


Chel-Hun Choi

Reginald Williams

Yvonne Gathright

Jennifer Martinez

genejock@helix.nih.gov





Icahn School
of Medicine at
**Mount
Sinai**

Challenges in collecting and pre-analytical processing of tissue: the human arterial wall

Chiara Giannarelli, MD, PhD

Assistant Professor of Medicine, Cardiology

Assistant Professor of Genetics and Genomics Sciences



Icahn School of Medicine at Mount Sinai

NIH Common Fund
HuBMAP / SCAP Mini Workshop
June 28, 2017
Neuroscience Center,
Bethesda, MD




Time of Flight Mass Cytometry (CyTOF)


Time-of-flight



Antibodies labeled with elemental isotopes



Quadrupole




ICP



Nebulizer


Heavy (>100 Da)
Reporter atomic ions

Light (<100 Da)
Overly abundant ions




| | Element | | | | | | | | | |
|--------|---------|---|---|---|-----|---|--|--|--|--|
| | A | B | C | D | ... | J | | | | |
| Cell 1 | 3 | 8 | 9 | 7 | ... | 8 | | | | |
| Cell 2 | 1 | 8 | 6 | 5 | ... | 4 | | | | |
| Cell 3 | 9 | 9 | 4 | 5 | ... | 7 | | | | |
| ... | | | | | | | | | | |

.FCS file




Experimental Pipeline

CyTOF Single-Cell Analysis



viSNE tissue vs. PBMCs



Lai, Cytometry 2015.



Amir, Nature Biotechnology 2013

IMMUNOTHERAPY



In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide

Romain Remark,¹ Taha Merghoub,² Niels Grabe,³ Geert Litjens,³ Diane Damotte,^{4,5} Jedd D. Wolchok,² Miriam Merad,^{1,*†} Sacha Gnjatic^{1,*†}


Multiplexed IHC for Validation and Tissue Discrimination



Experimental Workflow: challenges



In the lab



90% of the challenges

1. Alteration of surface markers
2. Alteration of functional state
3. Incomplete or too harsh digestion
4. Minimize the digestion time: live cell recovery
5. Tissue debris (collagen, elastin, calcium deposits)
6. Blood contamination

Future Directions

5-years goals

1. Map the human immune system in the diseased human arterial wall
2. Extend our pipeline to other cell types: i.e. VSMC, ECs, fibroblasts
3. Map the healthy arterial wall
4. Understand the impact of age, gender, cardiovascular risk factors, treatments on cell diversity in health and disease

Future Directions

10-years goals

To identify of tissue-specific immune and other cell type variations to provide new mechanist insights for the rational design of immunotherapies in atherosclerosis and to preserve vascular health


Network-driven drug repositioning approaches to treat CAD

NIH LINCS Program



LIBRARY OF INTEGRATED NETWORK-BASED CELLULAR SIGNATURES

We are here!!!


siRNA on THP-1 Foam Cells



KD1 KD2 KD3 KD4




Compute Connectivity Score



Selection of FDA-approved Phase2a-ready drugs

calcitriol, Drug A



★ Indicates awardee institution



R21TR001739

Schematic representation of the computational workflow for the repositioning approach used to identify candidate drugs targeting RGN42.

Future Directions


10-years goals

To identify of tissue-specific immune and other cell type variations to provide new mechanist insights for the rational design of immunotherapies in atherosclerosis and to preserve vascular health



To integrate non-invasive imaging modalities for precision diagnosis and personalized treatments

Systems Biology of Human Atherosclerotic Arterial Wall

Gene networks




Protein Networks




Atherosclerotic plaque

Cellular Networks



Imaging



How to build an ideal future state

1. Standardized SOP across different lab
2. Data sharing policy to build a human atlas
3. Establish collaborative multidisciplinary environment for investigators
4. Rigorous collection of health and disease information for each individual
5. Interdisciplinary working groups (bioinformatics, biology, medical background)

Thank you !



Acknowledgements

Giannarelli Lab

Nayaab Khan
Pauline Mury
Peik Sean Chong
Roza Shamailova
Christian Pina

Mount Sinai PriSM

Miriam Merad
Adeeb Rahamn
El-ad David Amir
Seunghee Kim-Schulze
Aleksy Chudnovoskiy
Sasha Gnatic
Romain Remark

Vascular Surgery

Peter Faries

Neurosurgery

J Mocco
Ahmed J. Awad

Bioinformatics

Avi Maya'an
Simon Koplev
Nick Fernandez

Genetics Dept.

Johan Bjorkegren
Joel Dudley

Oxford University

Claudia Monaco

Thanks!



National Heart, Lung,
and Blood Institute

K23HL111339
R03HL135289





National Center
for Advancing
Translational Sciences

R21TR001739



Icahn School
of Medicine at
**Mount
Sinai**

Frederick National Laboratory for Cancer Research



Optical Microscopy and Analysis Laboratory

Stephen J. Lockett




<https://confocal.cancer.gov/cores/optical-microscopy-and-analysis-laboratory>

Capabilities

Standard:

- 3D confocal microscopy
- Live cell imaging
- High content
- Fluorescence Recovery After Photobleaching (FRAP)
- Förster Resonance Energy Transfer (FRET)
- Structured Illumination Microscopy (SIM)
- Software for cell segmentation, colocalization, deconvolution, visualization



Advanced:

- Photo-activation Localization Microscopy and Stochastic Optical Reconstruction Microscopy
- Fluorescence Correlation Spectroscopy (FCS)
- Intravital animal imaging
- Tissue clearing
- Lightsheet microscopy
- Fluorescence life-time imaging (FLIM)
- Multi-functional and multi-focus microscopy (MFM)
- Total internal reflection fluorescence (TIRF) microscopy
- Customized image analysis, e.g particle tracking

Drosophila Kidney, Dr. Steven Hou, CCR

High Quality Tissue and Cell Imaging


| | Criterion | Method |
|---------------------------|---|---|
| Sample | Physical tissue damage Good overall morphology | Visual assessment |
| Labeling | Correctly localized protein | Visual: in the correct cells, compare FP to antibody |
| Microscope | Spatial Resolution, Spherical aberration, chromatic aberration | Visual, quantitative measurement with fluorescent beads |
| Microscope | Spectral bleedthrough | Visual, spectral unmixing |
| Image Analysis | Segmentation accuracy | Use well-known algorithms: thresholding, watershed and compare to ground truth |

2D and 3D Cell and Nucleus Segmentation

Basic Research: Some interaction generally OK

Drug screening: Automatic. Some degree of error can be tolerated

Pathology: Mixture of automatic and interactive. Inherent sample heterogeneity.



EMT panel on mouse xenograft of human gastric cell line, MKN45. In collaboration with Dr. Robert Kinders, Leidos / DCTD

Algorithms for 3D Segmentation

Graph cut segmentation:


- One click per nucleus
- Plus correction points
- Finds optimal surface

The screenshot displays a software interface for 3D segmentation, organized into two main columns: 'Original Image' and 'Segmented Image'. The interface is divided into three rows, each representing a different view of the data.


- Top Row:** Shows a top-down view of a circular arrangement of nuclei. The 'Original Image' shows the raw data, and the 'Segmented Image' shows the same view with one nucleus highlighted in red. Controls include 'top', 'up', '18/34', 'down', and 'bot' buttons, and a 'Change default radius' slider set to 30.
- Middle Row:** Shows a side view of the nuclei. The 'Original Image' shows the raw data, and the 'Segmented Image' shows the same view with one nucleus highlighted in red. Controls include 'top_y', 'up_y', '56/256', 'down_y', and 'bot_y' buttons, and a 'Change theta divisions' slider set to 32.
- Bottom Row:** Shows another side view of the nuclei. The 'Original Image' shows the raw data, and the 'Segmented Image' shows the same view with one nucleus highlighted in red. Controls include 'top_x', 'up_x', '68/256', 'down_x', and 'bot_x' buttons, and a 'Change phi divisions' slider set to 3. A 'Change z interpolation' slider is also present.

At the bottom of the interface, there are three buttons: 'Browse for an image', 'Save Segmentation', and 'Load previous images'. The dimensions of the segmented image are displayed as 'Dimensions: 34x 256x256'.


3D Segmentation Results




Volume rendering of low density of nuclei



Automatic segmentation can be trusted




Volume rendering of high density of nuclei



Need semi-interactive segmentation

3D Ground Truth for Validation


- 1) Segment actual 3D images as accurately as possible.
- 2) Treat the segmented image as the “perfect” image.
- 3) Artificially reintroduce the distortions of 3D microscopy: 3D PSF and noise, then use this image to test segmentation methods



Where we are now

Where we are at:

Grind and bind -> single, disaggregated cell analysis -> *in situ* molecular profiling



Gerdes et al, PNAS,
2013


Five Years from Now

In situ molecular profiling -> tissue / cell / nucleus structure -> phenotype

- SOPs for:
- tissue collection
 - staining
 - clearing
 - 3D image acquisition
 - 3D image analysis
 - visual representation of results

190 μm

*Image acquired with two photon (2P)
3D microscopy of TDE cleared tissue*



2017 HuBMAP Mini-workshop: Data Analysis, Standards, and Benchmarks for Single Cell Analysis

Junhyong Kim
University of Pennsylvania

Questions

- Is there benchmark data to compare new experimental or computational methods?
- How do we establish material standards such as specific cells or spike-in RNA?
- What metadata about calibration is important to know?
- What information is important to collect about the sample and its preparation?

Questions

- How can we work together with manufacturers to build standards into their methods?
- Does an ontology need to be established for single cell analysis?
- How can we associate single cells to tissue orientation information? More generally, how can data be organized from the single cell scale to whole organism scale?
- What are the common data elements between imaging and sequencing assays? Is there a common header we can use for all data, similar to FITS or DICOM?

Agenda:

- Overview (3:00-3:15)
- Breakout sessions (3:20-4:00)
- Summary of breakout sessions and synthesis (4:10-5:00)


Breakout Sessions

- Material Standards and Benchmarks
- Calibration, QC, and Instruments
- Experimental Designs, Ontologies, and Metadata
- Data Integration, Scale Alignment, and Data Analysis

Material Standards and Benchmarks

- Standard Cells?
- Control RNA?
- Compendium Data as Benchmarks?

Distribution of ERCCs



ERCC probes: 20 levels spanning 10^6 range


Calibration, QC, and Instruments

- Can there be an instrument calibration protocol?
- Quality Control protocol?
- Commercial instruments: standards and comparisons?

Cells



40-fold



| | |
|---|--------|
| Estimated Number of Cells | 2,262 |
| ce WS257 Estimated Number of Cell Partitions | 1,482 |
| cb WS257 kona Estimated Number of Cell Partitions | 827 |
| ce WS257 Fraction Reads in Cells | 22.0% |
| cb WS257 kona Fraction Reads in Cells | 60.0% |
| Mean Reads per Cell | 22,466 |

Experimental Designs, Ontologies, and Metadata

- Single cell sampling?
- Molecular biology?
- Standardized information models (ontologies) and information capture for provenance?

Anatomy

Pathology
Surgeon/procedure

Case Record
Consent IRB
Subject
Case Record'
Consent IRB
Subject

Sample
Sample
Sample



RNA
RNA

archive




cDNA → aRNA → Seq Lib
Seq Lib

Intact
Slice
Slice
Cells
Cells

Protocol
Phenotype
Handler
Dates

Protocol
Reagents
Handler
Source
QC (e.g., Bioanalyzer)


Sampling Variance Associated with RNA sequencing




Data Integration, Scale Alignment, and Data Analysis

- What are the common data elements between imaging and sequencing assays?
- How do we integrate information from different modalities?
- What are the signal to noise characteristics of various single cell platforms?
- How do we align information from single cell scales, to tissues, to organs, to whole bodies?

Replicate variance as a function of expression levels




Scale Alignment



6001 Executive Boulevard

Google



Woodmont Country Club

Lighthouse Tofu & Barbecue Restaurant

Parklawn Cemetery

Gilly's Craft Beer & Fine Wine


6001 Executive Boulevard

North Bethesda

The Mansion At Strathmore

The Home Depot


Google



6001 Executive Boulevard

20um

Google



10^5 scale

Google

Breakout Sessions

- Material Standards and Benchmarks
- Calibration, QC, and Instruments
- Experimental Designs, Ontologies, and Metadata
- Data Integration, Scale Alignment, and Data Analysis

<http://discourse.singlecellbiology.org>